Needham has recently reiterated Immuneering Corp (IMRX) stock to Buy rating, as announced on March 15, 2024, according to Finviz. Earlier, on March 15, 2024, TD Cowen had reduced the stock from a Outperform to Market Perform. Jefferies also reduced Hold rating with a price target of $3. Additionally, Needham initiated Buy rating on December 1, 2023, with a target price of $20. Oppenheimer analysts, in their report published on June 26, 2023, also resumed Outperform rating for Immuneering Corp’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Immuneering Corp (IMRX) Stock Trading Recap
On Monday, Immuneering Corp (IMRX) stock saw a decline, ending the day at $2.49 which represents a decrease of $-0.17 or -6.39% from the prior close of $2.66. The stock opened at $2.61 and touched a low of $2.44 during the day, reaching a high of $2.7. The volume of shares traded was 1.16 million falling short of the average volume of 6.26 million.
IMRX Stock Performance and Moving Averages
In recent trading, Immuneering Corp (IMRX) stock price has shown some volatility, fluctuating -13.24% over the last five trades and 114.66% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -9.45%, and it has gained 112.82% in the previous three months. Currently, IMRX is trading at 22.68%, 65.57%, and -21.13% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, IMRX, a Healthcare sector stock, is trading -72.33% below its 52-week high but remains 149.00% above its 52-week low. The Average True Range (ATR) (14 days) of 0.42 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Immuneering Corp’s Profitability and Valuation Ratios
Immuneering Corp’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -9.45%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Immuneering Corp’s market capitalization stands at $73.83 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 1.11, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 29.18% of Immuneering Corp (IMRX)’s shares, while financial institutions hold 32.39%.
Notable insider trades include Cormorant Asset Management, LP, 10% Owner at Immuneering Corp (IMRX), who sold 400000 shares on Apr 01 ’24, at $2.9 each, totaling $1.16 million. On Mar 14 ’24, Cormorant Asset Management, LP, 10% Owner, sold 509091 shares for $3.72 each, amounting to $1.89 million.
